Breaking News, Trials & Filings

Alligator Appoints Theradex as Study CRO

The phase I study is of ATOR-1015 for the treatment of metastatic cancer

Alligator Bioscience has appointed Theradex Oncology as the CRO for the planned phase I study of ATOR-1015 for the treatment of metastatic cancer. The study is expected to commence in the second half of 2018.   The upcoming clinical phase I study is a first-in-human dose escalation study in patients with metastatic cancer. The study will be conducted at five sites in Sweden and Denmark.   “Engaging Theradex is a key step towards starting our clinical phase I study with ATOR...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters